Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
The trademark rights for these brands will be transferred to Lupin by March next year.
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
The product will be manufactured at Lupin’s Somerset facility in the US
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Subscribe To Our Newsletter & Stay Updated